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1  | WHAT IS KNOWN AND OBJEC TIVE
Tacrolimus is commonly used in the treatment of immunologic rejec‐
tion after organ transplantation. It is a potent immunosuppressive 
macrocyclic compound that binds to the immunophilin FKBP‐12.1,2 
Despite the improvement of clinical outcome by tacrolimus, its use 
is associated with serious limitations. Tacrolimus has a narrow ther‐
apeutic window, and its pharmacokinetics shows a great variability 
between individuals.3 Therefore, the development of a predose bio‐
marker for predicting individual variability in tacrolimus metabolism 
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Abstract
What is known and objective: Personalized treatment with tacrolimus has remained 
a challenge. The present study aimed to evaluate the potential of an integrative ap‐
proach to predict individual tacrolimus concentrations and dosages based on endog‐
enous	CYP3A4	phenotype,	CYP3A5	genotype	and	clinical	variables.
Methods: A random forest (RF) algorithm which incorporated an endogenous 
CYP3A4	 phenotype	 (assessed	 by	 urinary	 ratio	 of	 6β‐hydroxycortisol and 6β‐hy‐
droxycortisone to cortisol and cortisone), CYP3A5*3 genotype and other clinical de‐
terminants of tacrolimus disposition was performed in 182 medically stable renal 
transplant recipients.
Results and discussion: The	results	suggested	that	endogenous	CYP3A4	phenotype	
was the most important determinant of tacrolimus concentrations and dose require‐
ments. RF models provided high goodness of fit (R2) with .92 and .95 for the predic‐
tion of tacrolimus trough concentrations and dosages, respectively, as well as high 
predictability (Q2)	with	0.63	and	0.70,	respectively.	Significant	correlations	existed	
between experimental and predictive data.
What is new and conclusion: In	summary,	endogenous	CYP3A4	phenotype	is	a	criti‐
cal biomarker for the determination of tacrolimus disposition. This predictive RF ap‐
proach	based	on	CYP3A4	biomarker	with	 the	combination	of	CYP3A5*3 genotype 
and other clinical variables can be used for predicting tacrolimus concentrations and 
dosages, which may serve as a useful tool in individualized tacrolimus dosing.
K E Y W O R D S
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would be of considerable interest in order to optimize dosing regi‐
men in clinic.
Tacrolimus	 is	 mainly	 metabolized	 by	 cytochrome	 P450	 (CYP)	
3A4	and	CYP3A5	in	human.4,5	Of	note,	most	single	nucleotide	poly‐
morphisms	 (SNPs)	 for	 CYP3A4	 are	 unable	 to	 explain	 the	 inter‐in‐
dividual	 variability	 in	 CYP3A4	 enzymatic	 activity.	 In	 contrast,	 the	
CYP3A5*3 allele (A6896G), which is strongly related with CYP3A5 
expression, has a significant impact on the pharmacokinetics of oral 
tacrolimus.4 CYP3A5 non‐expressers (CYP3A5*3/*3 genotype) have 
a lower tacrolimus clearance resulting in markedly lower tacrolimus 
dosage when compared with CYP3A5 expressers (CYP3A5*1/*1 
and CYP3A5*1/*3 genotypes). However, such genetic information is 
not capable of explaining the residual inter‐individual variability in 
the pharmacokinetics of tacrolimus within CYP3A5 expressers or 
CYP3A5 non‐expressers, and therefore, the achievement of an in‐
dividual's dosing regimen based on genetic assays remains limited.6 
As	a	complementary	or	alternative	strategy,	an	endogenous	CYP3A4	
phenotype [assessed by the combined ratio of 6β‐hydroxycortisol 
and 6β‐hydroxycortisone	to	cortisol	and	cortisone	 in	urine	 (HOM)]	
has	been	developed	in	our	laboratory	to	determine	in	vivo	CYP3A4	
activity, which may serve as an effective strategy to overcome the 
limitations of genetic approaches.7 Taking into account advantages 
of	endogenous	CYP3A4	phenotype,	urinary	HOM	is	a	truly	non‐inva‐
sive biomarker for tacrolimus metabolism in renal transplant patients 
because of unnecessary administration of probe drugs to human and 
no serial blood sampling.6,7 Although a regression equation including 
endogenous	CYP3A4	phenotype,	CYP3A5	genotype	and	other	pa‐
tient characteristics, such as demographic parameters, haematology 
and blood chemistries, was established to predict tacrolimus metab‐
olism and dosage requirements, all of renal transplant recipients in 
this study were at stable stage between 1 and 2 years post‐trans‐
plantation.7 When the patients at different post‐transplantation peri‐
ods were included, however, a poor regression relationship (r	=	.244)	
for the prediction of tacrolimus metabolism based on endogenous 
CYP3A4	phenotype	was	found	(unpublished	data).	Actually,	tacroli‐
mus metabolism under renal transplantation conditions was compli‐
cated and could not be fully elucidated by linear regression.
On	 the	 basis	 of	 these	 earlier	 findings,	we	 aimed	 to	 developed	
a novel integrative approach by incorporating biomarkers of tac‐
rolimus	metabolism	 (endogenous	CYP3A4	phenotype	 assessed	 by	
urinary	HOM	and	CYP3A5*3	genotype)	and	other	clinical	variables	
(demographic parameters, haematology and blood chemistries), 
which may tailor immunosuppressive therapy to the specific needs 
of an individual patient. Accordingly, the random forest (RF) model, 
which was fitted for non‐linear or multicollinear relationships in a 
large sample size, has been widely applied in clinical studies.8‐11	Using	
urinary	CYP3A4	biomarker,	we	aimed	to,	for	the	first	time,	build	a	RF	
model, to make successful predictions of tacrolimus concentrations 
and dosages in a larger sample size of kidney transplant recipients 
who were at least 3 months post‐transplantation. Additionally, the 
relative	 importance	 of	 contributions	 of	 CYP3A4	 phenotype	 and	
CYP3A5*3	genotype	was	tested	as	well.
2  | MATERIAL S
2.1 | Chemicals and reagents
6β‐hydroxycortisol, 6β‐hydroxycortisone, cortisol and cortisone 
were	purchased	from	Sigma‐Aldrich.	They	were	of	at	least	98%	pu‐
rity. Acetonitrile, methanol and formic acid were of LC grade and 
purchased from Tedia (Tedia Company Inc). All other chemicals were 
of	AR	grade	available	from	commercial	sources	(Sinopharm	Chemical	
Reagent Co. Ltd).
2.2 | Patient eligibility
The study was performed in the 3rd Affiliated Hospital of Xiangya 
Medical	 Institute,	 Central	 South	 University.	 The	 present	 clinical	
trial was registered with the number of NCT01699360. All experi‐
mental details were performed in accordance with the Declaration 
of Helsinki and its amendments. The protocol was approved by the 
Ethical	 Committee	 of	 School	 of	 Pharmaceutical	 Sciences,	 Central	
South	University.	All	 patients	provided	written	 informed	consents	
before commencing the study.
To be eligible for this study, the patients should meet the fol‐
lowing criteria: receiving an immunosuppressive therapy contain‐
ing tacrolimus (tacrolimus capsules, Prograf®, Astellas Ireland Co. 
Ltd), mycophenolate mofetil (CellCept®, Roche) and prednisolone; 
tacrolimus administration with the twice‐daily doses for at least 
5 days; the first renal transplantation; be considered ineligible if 
they had liver and renal impairment (defined as the values of ALT 
and	AST	not	greater	 than	3‐fold	upper	 limit	of	normal	 range;	de‐
fined as the values of total bilirubin not greater than 2‐fold upper 
limit of normal range; defined as the values of serum creatinine 
lower	 than	 451	μmol/L); at least 18 years old. We also excluded 
the patients who had the following: an acute rejection episode or 
infection; multiple organ transplantation; abnormal physical exam‐
ination or laboratory tests; taking any other medications known 
to induce or inhibit CYP3A enzyme; and taking any caffeine‐ and 
grapefruit‐containing foods.
2.3 | Human study plan
All patients received tacrolimus (1.0‐8.0 mg/d), mycophenolate 
mofetil (0.36‐1.5 mg/d) and prednisolone (2.0‐30.0 mg/d) at regular 
interviews. Before tacrolimus administration, blood samples were 
collected for drug monitoring and CYP3A5*3 genotyping. The urine 
specimens were obtained at 08:00 am‐10:00 am time intervals and 
stored	at	−20°C	before	analysis	of	6β‐hydroxycortisol, 6β‐hydroxy‐
cortisone, cortisol and cortisone. The therapeutic monitoring of 
tacrolimus trough concentrations by microparticle enzyme immuno‐
assay (MEIA, Abbott) was routinely performed in clinical laboratory. 
Haematology, blood chemistries and urinalysis, and the demograph‐
ics of each patient as well as their comedication were tested and 
recorded.
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2.4 | The endogenous CYP3A4 phenotype assessed 
by HOM
A	developed	HPLC‐UV	method	was	 used	 for	 the	 assay	 of	 urinary	
6β‐hydroxycortisol, 6β‐hydroxycortisone, cortisol and cortisone lev‐
els.12	Urinary	HOM	was	calculated	by	the	ratio	of	6β‐hydroxycortisol 
and 6β‐hydroxycortisone to cortisol and cortisone in urine, using the 
amount of each compound excreted.
2.5 | CYP3A5*3 genotyping
DNA was collected according to the instruction of Genomic DNA 
Purification Kit (Promega). A previous reported polymerase chain re‐
action‐restriction fragment length polymorphism (PCR‐RFLP) assay 
was used for CYP3A5*3 genotyping.13 The individual genotype was 
further validated by sequencing assay (data not shown).
2.6 | Data analysis
2.6.1 | Statistical analysis
The CYP3A5*3 genotype frequencies were assessed for deviations 
from the Hardy‐Weinberg equilibrium examined using the chi‐
square test. The dose‐corrected blood concentration (C0/D) and 
weight‐corrected daily dosage (D/W) of Tac between CYP3A5*3 
genotypes	 were	 compared	 using	 a	 one‐way	 ANOVA	 followed	
by post hoc Bonferroni corrected t tests. All statistical analysis 
was	 performed	 by	 SPSS	 17.0	 and	 P value <.05 was considered 
significant.
2.6.2 | Random forest algorithm
Here, we employed the random forest (RF) algorithm to establish 
predictive model. The overview and theory on RF can be found at 
https ://www.stat.berke ley.edu/~breim an/Rando mFore sts/. RF, 
developed from the classification and regression trees methodol‐
ogy (CART), combines a forest of uncorrelated trees created with 
the CART procedure.14 Each tree is constructed by a randomly se‐
lected subset of training data. The remaining training data, which are 
called	‘out‐of‐bag’,	are	used	to	estimate	prediction	error	and	variable	
importance.15
The random forest package in R is available at https ://cran.r‐
proje ct.org/web/packa ges/rando mFore st/index.html. The RF 
algorithm grows a collection, called a forest, of the unpruned classi‐
fication trees and uses these for classifying a data point into one of 
the classes. Two types of randomness, bootstrap sampling of sam‐
ples and random selection of input features, are used in the algo‐
rithm to make sure that the classification trees grown in the forest 
are dissimilar and uncorrelated from each other. A forest is grown by 
using ntree bootstrapped samples, each of size N randomly drawn 
from the original data of N training samples with replacement. This 
first type of randomization helps to build an ensemble of trees and to 
increase diversity among the trees. In each bootstrap sample, about 
two‐thirds of the original training samples are used to grow a classi‐
fication tree. About one‐third of the samples are left, called ‘out‐of‐
bag’	samples.	These	samples	are	used	to	obtain	unbiased	estimates	
of correct classification rates and feature importance measure. The 
second type of randomness is used during building each tree. For 
each node of a tree, the RF algorithm randomly selects mtry features 
and uses only them to determine the best possible split using the Gini 
index as the splitting criterion. Predictions for test data are carried 
out either by the majority vote of classification trees or are based 
on a threshold selected by the user. The number of trees (ntree) to 
be grown is chosen appropriately to achieve low error rate of con‐
vergence. Finally, RF can produce scores or probability outputs that 
serve to rank predictions according to confidence and have a useful 
probabilistic interpretation.16
3  | RESULTS
A total of 182 medically stable kidney transplant recipients who 
were at least 3 months post‐transplant participated in this study 
and	a	total	of	343	data	of	specimens	were	collected.	All	parameters	
of	 renal	 transplant	 recipients	 (endogenous	 CYP3A4	 phenotype,	
CYP3A5*3 genotype, routine laboratory tests and demograph‐
ics, etc) were shown in Table 1. The frequencies of CYP3A5*1/*1, 
CYP3A5*1/*3 and CYP3A5*3/*3	 were	 6.59%,	 26.37%	 and	 67.03%,	
respectively. The chi‐square test indicated that the distribution 
of genotype frequencies was in accordance with Hardy‐Weinberg 
equilibrium (P > .05).
The C0/D ratios of tacrolimus in the CYP3A5*3/*3 genotype were 
significantly higher than those in the CYP3A5*1/*1 and CYP3A5*1/*3 
TA B L E  1   The parameters of renal transplant recipients
Parameter Value
Endogenous	CYP3A4	phenotype	(urinary	
HOM)
3.16	±	4.79
CYP3A5*3 genotype (expressors/
non‐expressors)
60/122
Age (y) 37.9	±	9.7
Gender (male/female) 136/46
Body weight (kg) 60.4	±	10.4
Height (cm) 165.6 ± 6.2
Body mass index (kg/m2) 22.0 ± 3.2
Post‐operative periods (h) 25	271.4	±	23	292.8
Glutamic‐pyruvic	transaminase	(U/L) 24.5	±	17.1
Glutamic‐oxalacetic	transaminase	(U/L) 21.0 ± 12.6
Total bilirubin (μmol/L) 13.4	±	4.6
Blood urea nitrogen (mmol/L) 8.7	±	35.1
Serum	creatinine	(μmol/L) 97.7	±	45.0
Serum	uric	acid	(μmol/L) 332.7	±	79.6
Comedication of calcium antagonists 
(with/without)
71/111
Note: Data:	mean	±	SD.
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genotypes (Figure 1). Meanwhile, the D/W ratios in the CYP3A5*3/*3 
group were markedly lower when compared with CYP3A5*1 carriers 
(CYP3A5*1/*1 and CYP3A5*1/*3	genotypes)	(Figure	2).	Our	findings	
were in accordance with the relationship between CYP3A5 geno‐
type and phenotype.
The RF prediction models were built on the combination of 
several parameters as shown in Table 1. Figure 3 presented the im‐
portance	of	all	variables,	which	indicated	the	endogenous	CYP3A4	
probe was the most major determinant of tacrolimus disposition. 
The performance of the models used to predict tacrolimus C0/D ra‐
tios and dosage were summarized in Table 2. The square correlation 
coefficients of fitting (R2) and the square correlation coefficients of 
cross‐validation (Q2) demonstrated that satisfactory prediction of 
tacrolimus metabolism and dosage requirements could be achieved 
using	RF	algorithm.	Figures	4	and	5	showed	that	good	correlations	
existed between experimental and predictive data.
4  | DISCUSSION
With the advances in personal genetic assays, CYP3A5*3 genotyping 
provides important explanation for individual variations in tacroli‐
mus pharmacokinetics.3 In accordance with previous study,3,6 our 
results also confirmed that CYP3A5*1/*1 and CYP3A5*1/*3 subjects 
displayed lower C0/D ratios and higher D/W ratios when compared 
with CYP3A5*3/*3 genotypes (Figures 1 and 2). As discussed above, 
however, genetic information has its own limitations. And so, the 
enzyme probes, which are used to estimate the patient's metabolic 
activity, may enable the optimization of tacrolimus dosing for an in‐
dividual patient as a complementary strategy.6,7
F I G U R E  1   The values of C0/D ratios of tacrolimus across the 
three	CYP3A5	genotypes	(CYP3A5*1/*1:	n	=	27;	CYP3A5*1/*3:	
n	=	75;	CYP3A5*3/*3:	n	=	241)
F I G U R E  2   The values of D/W ratios of tacrolimus across the 
three	CYP3A5	genotypes	(CYP3A5*1/*1:	n	=	27;	CYP3A5*1/*3:	
n	=	75;	and	CYP3A5*3/*3:	n	=	241)
F I G U R E  3   The importance of the variables for the prediction 
of tacrolimus disposition: (A) tacrolimus C0/D ratios (n = 229); 
(B)	tacrolimus	dosages	(n	=	229).	HOM,	urinary	ratio	of	6β‐
hydroxycortisol and 6β‐hydroxycortisone to cortisol and cortisone; 
CR, serum creatinine; TBIL, total bilirubin; ALT, glutamic‐pyruvic 
transaminase;	AST,	glutamic‐oxalacetic	transaminase;	Bun,	blood	
urea	nitrogen;	Ua,	serum	uric	acid;	BMI,	body	mass	index;	and	POT,	
post‐operative periods
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Midazolam clearance, one of the most common probes for in vivo 
CYP3A4	 activity,	 correlated	 significantly	 with	 tacrolimus	metabo‐
lism.6	It	has	been	proved	that	approximately	60%	of	variability	in	tac‐
rolimus dose requirements and clearance could be explained by the 
combination of midazolam clearance, CYP3A5*3 genotype and hae‐
matocrit.6 However, administration of midazolam would introduce 
potential inconvenience to patients because of the pharmacologi‐
cal effects as a central nervous system depressant; thus, the use of 
endogenous	substances	as	biomarkers	of	CYP3A4	phenotype	is	the	
simplest	and	safest	way	to	sequentially	monitor	in	vivo	CYP3A4	ac‐
tivity.	In	our	previous	study,	an	endogenous	CYP3A4	probe	assessed	
by	urinary	HOM	was	developed	in	renal	transplant	recipients.7 The 
previous findings also suggested that the relationships between 
tacrolimus metabolism and some of clinical variables were complex 
due to significant differences in the physical condition of patients.7 
As a multivariate statistical model, RF algorithm that depended on 
the combination of individual parameters (Table 1) might be a use‐
ful approach to describe these complicated relationships. Table 2 
showed that our predictive model had high goodness of fit (R2) with 
.92 and .95 for the prediction of tacrolimus C0/D ratios and dosages, 
respectively, as well as high predictability (Q2)	with	0.63	and	0.70,	
respectively. Also there were significant correlations between ex‐
perimental and predictive data, indicating a good and acceptable 
prediction of tacrolimus concentrations and dosage requirements in 
renal	transplant	recipients	(Figures	4	and	5).
Figure 3 represented the relative importance of contributions of 
each	variable.	The	endogenous	CYP3A4	probe	was	much	more	im‐
portant than CYP3A5*3 polymorphisms and other clinical variables. 
Consideration with the fact that P‐glycoprotein (P‐gp) limits the 
bioavailability of tacrolimus as an efflux transporter,4 MDR1	3435T	
allele,	one	of	the	most	studied	SNPs	of	P‐gp,	was	tested	here.	The	re‐
sults indicated that MDR1 polymorphism did not affect the predict‐
ability with tacrolimus disposition (Figure 3), which was consistent 
with previously negative reports.3 Currently, therapeutic monitor‐
ing of tacrolimus mainly depends on the analysis of blood concen‐
tration when tacrolimus is administered. Despite therapeutic drug 
monitoring‐based dosage adjustment of tacrolimus has been con‐
ducted for a long time in clinic, this approach is inconvenient after all 
because it needs multiple blood sampling. In contrast, our findings 
suggested a non‐invasive biomarker in urine for evaluating individual 
pharmacokinetics of tacrolimus, which could serve as an alternative 
way to monitor tacrolimus levels during the therapy. Consideration 
of circadian rhythm of glucocorticoid secretion, the urine samples 
of peak levels of glucocorticoid at the time interval of 08:00 am to 
10:00 am were easily acquired at present, and our preliminary study 
(unpublished data) also demonstrated that the value of endogenous 
CYP3A4	probe	at	 this	 interval	correlated	strongly	with	that	at	 the	
time	interval	within	24	hours	(r	=	.740,	P < .01).
Moreover, by selecting a population of medically stable kidney 
transplant recipients who were at least 3 months after transplan‐
tation in our study, there were no patients with hepatic and renal 
dysfunction which might alter tacrolimus pharmacokinetics in vivo.17 
Tacrolimus disposition can be affected by changes in patients' con‐
ditions, such as hepatic and renal dysfunction, and drug‐drug inter‐
actions, which may alter the validity of our predictive algorithm in 
such	post‐transplantation	conditions.	Of	importance,	however,	this	
Predictive parameters RMSEFit R2 (n = 229) RMSECV Q2 (n = 114)
C0/D ratios 0.59 .92 1.09 0.63
Tacrolimus dosage 0.33 .95 0.79 0.70
Note: C0/D	ratios:	dose‐corrected	trough	concentration	of	tacrolimus;	RMSEFit:	the	root‐mean‐
squared error of fitting; R2:	the	square	correlation	coefficients	of	fitting;	RMSECV:	the	root‐mean‐
squared error of cross‐validation; Q2: the square correlation coefficients of cross‐validation.
TA B L E  2   The predictive results of 
tacrolimus C0/D ratios and dosage in 
Chinese renal transplant recipients using 
RF algorithm
F I G U R E  4   The relationship between experimental and 
predictive values of C0/D ratios of tacrolimus in Chinese renal 
transplant	recipients	(n	=	114)
F I G U R E  5   The relationship between experimental and 
predictive values of tacrolimus dosages in Chinese renal transplant 
recipients	(n	=	114)
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did not imply that our approach would be invalid for predicting indi‐
vidual pharmacokinetics of tacrolimus among patients with different 
conditions since these clinical factors mentioned above altered tac‐
rolimus	metabolism	through	changes	in	CYP3A4	activity,	which	was	
focused on at present. It would be interesting to verify this hypoth‐
esis in a more diverse population.
5  | WHAT IS NE W AND CONCLUSION
In	 summary,	 endogenous	CYP3A4	phenotype	 assessed	by	urinary	
HOM	is	a	critical	biomarker	for	the	determination	of	tacrolimus	dis‐
position, which plays a much more important role than CYP3A5*3 
genotype and other clinical variables. Finally, we propose a novel RF 
integrative approach for predicting tacrolimus concentrations and 
dosages	in	renal	transplant	recipients.	This	CYP3A4	biomarker‐based	
prediction algorithm with the incorporation of CYP3A5*3 genotype 
and other clinical factors can be of use to clinicians in optimizing 
individual dosages of oral tacrolimus prior to treatment, which may 
improve therapeutic efficacy but minimize adverse effects.
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